BiotechTube

Ritlecitinib higher dose + Ritlecitinib lower dose

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Alopecia Areata

Conditions

Severe Alopecia Areata

Trial Timeline

Sep 10, 2025 → Jun 26, 2030

NCT ID
NCT07029828

About Ritlecitinib higher dose + Ritlecitinib lower dose

Ritlecitinib higher dose + Ritlecitinib lower dose is a phase 3 stage product being developed by Pfizer for Severe Alopecia Areata. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07029828. Target conditions include Severe Alopecia Areata.

What happened to similar drugs?

20 of 20 similar drugs in Severe Alopecia Areata were approved

Approved (20) Terminated (6) Active (0)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅tacrolimusAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅CefiderocolShionogiApproved
✅Donepezil HClEisaiApproved
✅Donepezil Hydrochloride (Aricept)EisaiApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07029828Phase 3Recruiting

Competing Products

20 competing products in Severe Alopecia Areata

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Drotrecogin alfa (activated)Eli LillyPhase 2
35
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
enzalutamideAstellas PharmaPhase 1
29
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
CefiderocolShionogiApproved
50
eritoran tetrasodium + PlaceboEisaiPhase 3
40
Donepezil HClEisaiApproved
43
Donepezil Hydrochloride (Aricept)EisaiApproved
35
KHK4827 + PlaceboKyowa KirinPhase 3
40